A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of Cizutamig in Patients With Thyroid Eye Disease
Status: Recruiting
Location: See all (14) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this study is to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with thyroid eye disease (TED).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• 18-75 years old at the time of signing the Informed Consent Form
• Diagnosis of Graves' Disease with active, moderate to severe TED in accordance with the Chinese Guidelines for the Diagnosis and Treatment of Thyroid-Associated Ophthalmology (2022) at Screening and Day 1
Locations
Other Locations
China
Peking Union Medical College Hospital
RECRUITING
Beijing
The Third Xiangya Hospital of Central South University
RECRUITING
Changsha
Xiangya Hospital of Central South University
RECRUITING
Changsha
Sichuan Provincial People's Hospital
RECRUITING
Chengdu
The Second Hospital of Dalian Medical University
RECRUITING
Dalian
The Eighth Affiliated Hospital of Southern Medical University (Shunde District People's Hospital of Foshan City)
RECRUITING
Foshan
Fujian Medical University Union Hospital
RECRUITING
Fuzhou
Guangdong Provincial People's hospital
RECRUITING
Guangzhou
The Second Hospital of Anhui Medical University
RECRUITING
Hefei
Qilu Hospital of Shandong University
RECRUITING
Jinan
The First Affiliated Hospital of Nanchang University
RECRUITING
Nanchang
Shanghai Ninth People's hospital Shanghai Jiaotong University school of medicines
RECRUITING
Shanghai
The First Affiliated Hospital of China Medical University
RECRUITING
Shenyang
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING
Wuhan
Contact Information
Primary
Martin Zhuang
martin@candidrx.com
+86 13918519658
Time Frame
Start Date: 2026-05-08
Estimated Completion Date: 2028-06-30
Participants
Target number of participants: 38
Treatments
Experimental: Cizutamig
Related Therapeutic Areas
Sponsors
Leads: Candid Therapeutics